BiotechTube

Pariet

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Stomach Ulcer

Conditions

Stomach Ulcer, Duodenal Ulcer

Trial Timeline

Jul 23, 2020 → Sep 22, 2022

NCT ID
NCT05208268

About Pariet

Pariet is a pre-clinical stage product being developed by Eisai for Stomach Ulcer. The current trial status is completed. This product is registered under clinical trial identifier NCT05208268. Target conditions include Stomach Ulcer, Duodenal Ulcer.

What happened to similar drugs?

1 of 8 similar drugs in Stomach Ulcer were approved

Approved (1) Terminated (1) Active (6)
✅E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
🔄epoetin alfaJohnson & JohnsonPhase 3
🔄Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
🔄Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
❌Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
🔄ECC + FOLFIRIRochePhase 3
🔄Capecitabine + OxaliplatinRochePhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05208268Pre-clinicalCompleted

Competing Products

20 competing products in Stomach Ulcer

See all competitors
ProductCompanyStageHype Score
EO-3021 + Ramucirumab (CYRAMZA®) + DostarlimabCSPC Pharmaceutical Group LimitedPhase 1
21
E0671 + rabeprazole sodium + E0671 placeboEisaiApproved
43
Ramucirumab + Placebo + Oxaliplatin + Leucovorin + 5-FluorouracilEli LillyPhase 2
35
Ramucirumab + Capecitabine + Cisplatin + S-1 + OxaliplatinEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
39
epoetin alfaJohnson & JohnsonPhase 3
40
MK0782MerckPhase 2
35
Pembrolizumab + Cisplatin + 5-fluorouracil + oxaliplatin + capecitabine + Placebo for PembrolizumabMerckPhase 3
40
Avelumab + Oxaliplatin + 5-Fluorouracil + Leucovorin + Capecitabine + Oxaliplatin + 5-Fluorouracil + Leucovorin + CapecitabineMerckPhase 3
40
Pembrolizumab + Cisplatin + 5-fluorouracil + Oxaliplatin + Capecitabine + Placebo for PembrolizumabMerckPhase 3
32
AUY922 + BYL719NovartisPhase 1
29
ECC + FOLFIRIRochePhase 3
40
Capecitabine + OxaliplatinRochePhase 3
40
Atezolizumab + Capecitabine + Oxaliplatin + DocetaxelRochePhase 2
39
Atezolizumab + Tiragolumab + Oxaliplatin + CapecitabineRochePhase 2
27
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, CapecitabineAmgenPhase 2
35
AMG 337AmgenPhase 1/2
32
AMG 337AmgenPhase 2
27
Cisplatin + S-1 + SunitinibPfizerPhase 1
29
axitinib + capecitabine + cisplatinPfizerPhase 1
29